EPISODE · Aug 24, 2022 · 1H 2M
Episode 4. Measurable Residual Disease in AML
from Blood Cancer Talks · host Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
2021 European LeukemiaNET MRD Working Party Consensus Guidelines: https://pubmed.ncbi.nlm.nih.gov/34724563/Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006
What this episode covers
In this episode, we discuss the techniques to assess measurable residual disease (MRD) in AML, clinical implications of MRD results, and future directions on MRD-guided patient management.
NOW PLAYING
Episode 4. Measurable Residual Disease in AML
No transcript for this episode yet
Similar Episodes
No similar episodes found.